# Evaluation of MK-1075 in Participants With Hepatitis C Virus (HCV) Infection (MK-1075-002)

> **NCT02392494** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 9 (actual)

## Conditions studied

- Hepatitis C

## Interventions

- **DRUG:** MK-1075

## Key facts

- **NCT ID:** NCT02392494
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04-28
- **Primary completion:** 2015-08-10
- **Final completion:** 2015-08-10
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2019-01-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02392494

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02392494, "Evaluation of MK-1075 in Participants With Hepatitis C Virus (HCV) Infection (MK-1075-002)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02392494. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*